The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Brief Title: A Dose-Escalation Study of OBP-801 in Patients With Advanced Solid Tumors
Official Title: A Phase 1a Dose-Escalation Study of OBP-801 in Patients With Advanced Solid Tumors
Study ID: NCT02414516
Brief Summary: This Phase 1a, single center, open-label, repeat dose study will evaluate the safety, efficacy, and Pharmacokinetics of ascending doses of OBP-801 in patients with advanced solid tumors.
Detailed Description:
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Barbara Ann Karmanos Cancer Institute, Detroit, Michigan, United States